Genmab — Maj 2019

E_L

Horizon Pharma is now Horizon Therapeutics plc. lol. Anyway, Continue to Expect Mid-2019 U.S. Biologics License Application (BLA) Submission for Teprotumumab . ( Teprotumumab has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA. If approved, teprotumumab would be the first and only approved treatment for active TED.) http://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-reports-strong-first-quarter-2019

Plimsoller

@ E L thank you. That is really good news.

peter12

Marshall Wace LLP holds a short position at 0.54 % in shares issued by Genmab A/S

E_L

New trial : Daratumumab, Ixazomib, & Dexamethasone With or Without Bortezomib in Patients With Newly Diagnosed Multiple Myeloma (DeRIVE) - https://clinicaltrials.gov/ct2/show/NCT03942224

peter12

De har nok skumle planer ...

E_L

I actually thought Ixazomib and bortezomib are sort of similar, both proteasome inhibitors , did not expect them to be used together

Plimsoller

(borsen.dk)

ienk1

Marshall Wace LLP has reduced his short position to 303580 shares issued by Genmab A/S 14/02 2019

Bulder

E L, you can see the explanation in experimental arm II. They don't get isa and bor at the same time.

E_L

ok, thks, i see it now

Bulder

+6 kroner på en lukkeauktion. Det er vist rekord.

Helge_LarsenPI-redaktør

E_L

jkj

nøgletal lidt dårligere end forventet

jkj

Den skal tales godt op til q&A ellers er der ingen belønning.

Helge_LarsenPI-redaktør

Regnskabet er inden for skiven.

jkj

jeg syndes det er skræmmende at cashburn er blevet så stort at der ikke kan laves et plus.

E_L

so if they had slowed down their work and hiring just to get a small plus you would have been happier...?

Legolas23

Børsen i vanlig prosa

Legolas23

(borsen.dk)